These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7860133)

  • 1. 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer.
    Gasparini G; Barbareschi M; Boracchi P; Bevilacqua P; Verderio P; Dalla Palma P; Ménard S
    Int J Cancer; 1995 Mar; 60(5):604-10. PubMed ID: 7860133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.
    Bevilacqua P; Barbareschi M; Verderio P; Boracchi P; Caffo O; Dalla Palma P; Meli S; Weidner N; Gasparini G
    Breast Cancer Res Treat; 1995; 36(2):205-17. PubMed ID: 8534868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
    Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
    J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human breast cancer: survival from first metastasis. Breast Cancer Study Group.
    Koenders PG; Beex LV; Kloppenborg PW; Smals AG; Benraad TJ
    Breast Cancer Res Treat; 1992; 21(3):173-80. PubMed ID: 1515652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
    Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
    Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
    Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
    Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
    Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
    Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
    Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
    Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor.
    Göhring UJ; Scharl A; Heckel C; Ahr A; Crombach G
    Arch Gynecol Obstet; 1995; 256(3):139-46. PubMed ID: 7574906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
    Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
    Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.